Celon Pharma S.A.

Warsaw Stock Exchange CLN.WA

Celon Pharma S.A. Capital Expenditure for the year ending December 31, 2023: USD -8.32 M

Celon Pharma S.A. Capital Expenditure is USD -8.32 M for the year ending December 31, 2023, a -7.53% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Celon Pharma S.A. Capital Expenditure for the year ending December 31, 2022 was USD -7.74 M, a 24.35% change year over year.
Celon Pharma S.A. Capital Expenditure for the year ending December 31, 2021 was USD -10.23 M, a 61.47% change year over year.
Celon Pharma S.A. Capital Expenditure for the year ending December 31, 2020 was USD -26.55 M, a -55.34% change year over year.
Celon Pharma S.A. Capital Expenditure for the year ending December 31, 2019 was USD -17.09 M, a 5.09% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Warsaw Stock Exchange: CLN.WA

Celon Pharma S.A.

CEO	Dr. Maciej Wieczorek Ph.D.
IPO Date	Feb. 17, 2017
Location	Poland
Headquarters	ul. Ogrodowa
Employees	566
Sector	Healthcare
Industries Pharmaceuticals Biotechnology

Description

Celon Pharma S.A., an integrated pharmaceutical company, researches, manufactures, and markets pharmaceutical products and preparations. The company operates through Generic Drug and Innovative segments. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. is a subsidiary of Glatton Sp. z o.o.

Key trends

Past 5 years